1
|
Alanzi A, Husain F, Husain H, Hanif A, Baskaradoss JK. Does the severity of untreated dental caries of preschool children influence the oral health-related quality of life? BMC Oral Health 2023; 23:552. [PMID: 37563589 PMCID: PMC10416462 DOI: 10.1186/s12903-023-03274-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2023] [Accepted: 07/31/2023] [Indexed: 08/12/2023] Open
Abstract
AIM To assess the impact of untreated dental caries and its severity on the oral health-related quality of life (OHRQoL) of Kuwaiti preschool children and their caregivers. METHODS Participants were 4- and 5-year-old kindergarten children attending preselected public schools from one of the Governorates in Kuwait. Early childhood caries (ECC) was evaluated by clinical examinations and presented using decayed, missed, filled teeth/surface (dmft/dmfs). The clinical consequences of untreated dental caries were assessed using the pufa (pulp, ulcers, fistula, abscess) index for primary teeth. A structured questionnaire obtained demographic information of children and their caregivers. OHRQoL was assessed using the Arabic version of Early Childhood Oral Health Impact Scale (A-ECOHIS). RESULTS Among the 334 participants, 171 were kindergarten level-1 (KG1), and 163 were level-2 (KG2). The overall prevalence of dental caries was 78.9% for KG1 children and 67.4% for KG2 children. Decayed teeth were the main component for both dmft (84%) and dmfs (68%). The total mean (SD) pufa score was 0.54 (1.5), and about 19.2% of participants had at least one tooth with pufa > 0. A total of 207 A-ECOHIS were completed. Both family and child impact scores were significantly higher for children with a dmft score of 1 or more (p < 0.001) or with one or more pufa (p < 0.001). Child impact section scores were significantly higher with the increasing degrees of untreated caries (dt) (p = 0.004). CONCLUSION The severity of untreated dental caries and caries experience had a negative impact on the OHRQoL of Kuwaiti preschool children and their families. Using the pufa index had provided additional information about the effect of the caries severity on the OHRQoL than assessing the caries experience alone.
Collapse
Affiliation(s)
- A Alanzi
- College of Dentistry, Kuwait University, Jabriya, Kuwait.
| | - F Husain
- College of Dentistry, Kuwait University, Jabriya, Kuwait
| | - H Husain
- Ministry of Health, Kuwait City, Kuwait
| | - A Hanif
- College of Dentistry, Kuwait University, Jabriya, Kuwait
| | | |
Collapse
|
2
|
ul Haq Z, Mehmood U, Tariq S, Hanif A, Nawaz H. Role of meteorological parameters with the spread of Covid-19 in Pakistan: application of autoregressive distributed lag approach. Int J Environ Sci Technol (Tehran) 2023:1-22. [PMID: 37360555 PMCID: PMC10249560 DOI: 10.1007/s13762-023-04997-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 12/04/2022] [Accepted: 05/08/2023] [Indexed: 06/28/2023]
Abstract
This research focuses on the impacts of different meteorological parameters (temperature, humidity, rainfall, and evapotranspiration) on the transmission of Covid-19 in the administrative regions and provinces of Pakistan, i.e., Azad Jammu and Kashmir, Gilgit Baltistan, Khyber Pakhtunkhwa, Islamabad, Punjab, Sindh, and Balochistan from June 10, 2020, to August 31, 2021. This study analyzes the relation between Covid-19-confirmed cases and the meteorological parameters with the help of the autoregressive distributed lag model. In this research, additional tools (t-statistics, f-statistics, and time series analysis) are used for the motive of examining the linear relationship, the productivity of the model, and for the significant association between dependent and independent variables, lnccc and lnevp, lnhum, lnrain, lntemp, respectively. Values of t-statistics and f-statistics reveal that variables have a connection and individual significance for the model exist. Time series display that the Covid-19 spread increased from June 10, 2020, to August 31, 2021, in Pakistan. Temperature positively influenced the Covid-19-confirmed cases in all provinces of Pakistan in the long run. Evapotranspiration and rainfall influenced positively, while specific humidity influenced negatively on the confirmed Covid-19 cases in Azad Jammu Kashmir, Khyber Pakhtunkhwa, and Punjab. Specific humidity had a positive impact, while evapotranspiration and rainfall had the negative impact on the Covid-19-confirmed cases in Sindh and Balochistan. Evapotranspiration and specific humidity influenced positively, while rainfall influenced the Covid-19-confirmed cases negatively in Gilgit Baltistan. Evapotranspiration influenced positively, while specific humidity and rainfall influenced negatively on the Covid-19-confirmed cases in Islamabad. Supplementary Information The online version contains supplementary material available at 10.1007/s13762-023-04997-4.
Collapse
Affiliation(s)
- Z. ul Haq
- Remote Sensing, GIS and Climatic Research Lab, National Center of GIS and Space Applications, Centre for Remote Sensing, University of the Punjab, New-Campus, Lahore, Pakistan
| | - U. Mehmood
- Remote Sensing, GIS and Climatic Research Lab, National Center of GIS and Space Applications, Centre for Remote Sensing, University of the Punjab, New-Campus, Lahore, Pakistan
- Department of political science, University of management and technology, Lahore, Pakistan
| | - S. Tariq
- Remote Sensing, GIS and Climatic Research Lab, National Center of GIS and Space Applications, Centre for Remote Sensing, University of the Punjab, New-Campus, Lahore, Pakistan
- Remote Sensing, GIS and Climatic Research Lab, National Center of GIS and Space Applications, Department of Space Science, University of the Punjab, New-Campus, Lahore, Pakistan
| | - A. Hanif
- Remote Sensing, GIS and Climatic Research Lab, National Center of GIS and Space Applications, Department of Space Science, University of the Punjab, New-Campus, Lahore, Pakistan
| | - H. Nawaz
- Remote Sensing, GIS and Climatic Research Lab, National Center of GIS and Space Applications, Centre for Remote Sensing, University of the Punjab, New-Campus, Lahore, Pakistan
| |
Collapse
|
3
|
Sharif F, Ahmad A, Gilani S, Bacha R, Hanif A. Ultrasound Guided Dry Needling for Treatment of Patients with Jumper’s Knee: a Study Protocol for Randomized Controlled Trial. Muscles Ligaments Tendons J 2022. [DOI: 10.32098/mltj.02.2022.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
4
|
Sharif F, Ahmad A, Gilani S, Bacha R, Hanif A, Ahmed S. Musculoskeletal Symptoms in Patients Recovering from COVID-19. Muscles Ligaments Tendons J 2022. [DOI: 10.32098/mltj.01.2022.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
5
|
Hanif A, Mujtaba G, Goksu S, Sheikh H. 191P Real-world data (RWD) on the long-term outcomes of the addition of carboplatin to standard neoadjuvant chemotherapy in triple-negative stage I-III breast cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Hanif A, Saeed M, Rasheed F, Hussain S, Riaz S, Ahmad M, Ain N. Acinetobacter Spp: Resistance and therapeutic decisions at the turn of the novel millennium. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
7
|
Macintyre G, Goranova TE, Silva DD, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD. Abstract AP09: COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA. Clin Cancer Res 2019. [DOI: 10.1158/1557-3265.ovcasymp18-ap09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: The genomic complexity of profound copy-number aberration has prevented effective molecular stratification of high grade serous ovarian carcinoma (HGSOC). Recent algorithmic advances have enabled interpretation of complex genomic changes by identifying mutational signatures—genomic patterns that are the imprint of mutagenic processes accumulated over the lifetime of a cancer cell. We hypothesized that specific features of copy-number (CN) abnormalities could represent the imprints of distinct mutational processes, and developed methods to identify signatures from copy-number features in HGSOC.
METHODS: We derived copy-number signatures from absolute copy number profiles from 253 primary and relapsed HGSOC samples from 132 patients in the BriTROC-1 cohort using low-cost shallow whole-genome sequencing (sWGS; 0.1×). A subset of 56 of these cases had deep whole-genome sequencing (dWGS) performed for mutation analysis and comparison with sWGS data. Independent validation was performed using 112 dWGS HGSOC cases from PCAWG and 415 HGSOC cases with SNP array and whole exome sequence from TCGA. CN signature exposures were correlated with mutation data, SNV signatures, and other measures derived from deep WGS and exome sequencing to identify statistically significant genomic associations using a false discovery rate <0.05.
RESULTS: We identified 7 CN signatures that provided a molecular framework to rederive the major defining elements of HGSOC genomes, including defective homologous recombination (HRD), tandem duplication, amplification of CCNE1 and amplification-associated fold-back inversions. Almost all patients with HGSOC demonstrated a mixture of signatures indicative of combinations of mutational processes, including those with early driver events such as BRCA2 mutation (in addition to HRD signatures). High exposure to CN signature 3, characterised by BRCA1/2-related HRD, was associated with improved overall survival. Conversely, high exposure to signature 1, which was characterised by oncogenic RAS signaling (including NF1, KRAS and NRAS mutation), predicted platinum-resistant relapse and poor survival.
CONCLUSIONS: HGSOC lacks clinically-relevant patient stratification, which is reflected in poor survival and is a significant barrier to precision medicine. Copy-number signature exposures at diagnosis predict both overall survival and the probability of platinum-resistant relapse. Our results suggest that early TP53 mutation, the ubiquitous initiating event in HGSOC, may permit multiple mutational processes to co-evolve, potentially simultaneously and that additional signature exposures may alter the risk of developing therapeutic resistance. Thus, our results suggest that HGSOC is a continuum of genomes.
We derived signatures using inexpensive sWGS of DNA from core biopsies. These approaches are rapid and cost effective, thus providing a clear path to clinical implementation. By dissecting the mutational forces shaping HGSOC genomes, our study paves the way to understanding extreme genomic complexity, as well as revealing the evolution of tumors as they relapse and acquire resistance to therapy.
Citation Format: Geoff Macintyre, Teodora E. Goranova, Dilrini De Silva, Darren Ennis, Anna M. Piskorz, Matthew Eldridge, Daoud Sie, Liz-Anne Lewsley, Aishah Hanif, Cheryl Wilson, Suzanne Dowson, Rosalind M. Glasspool, Michelle Lockley, Elly Brockbank, Ana Montes, Axel Walther, Sudha Sundar, Richard Edmondson, Geoff D. Hall, Andrew Clamp, Charlie Gourley, Marcia Hall, Christina Fotopoulou, Hani Gabra, James Paul, Anna Supernat, David Millan, Aoisha Hoyle, Gareth Bryson, Craig Nourse, Laura Mincarelli, Luis Navarro Sanchez, Bauke Ylstra, Mercedes Jimenez-Linan, Luiza Moore, Oliver Hofmann, Florian Markowetz, Iain A. McNeish, James D. Brenton. COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr AP09.
Collapse
Affiliation(s)
- Geoff Macintyre
- 1Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK,
| | | | - Dilrini De Silva
- 1Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK,
| | - Darren Ennis
- 2Institute of Cancer Sciences, University of Glasgow, G61 1QH, UK,
| | - Anna M. Piskorz
- 1Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK,
| | - Matthew Eldridge
- 1Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK,
| | - Daoud Sie
- 3VU University Medical Center, Amsterdam 1007 MB, The Netherlands,
| | - Liz-Anne Lewsley
- 4Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, G12 0YN, UK,
| | - Aishah Hanif
- 4Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, G12 0YN, UK,
| | - Cheryl Wilson
- 4Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, G12 0YN, UK,
| | - Suzanne Dowson
- 2Institute of Cancer Sciences, University of Glasgow, G61 1QH, UK,
| | | | - Michelle Lockley
- 6Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK,
- 7University College London Hospital, London, WC1E 6BD, UK,
| | | | | | - Axel Walther
- 10Bristol Cancer Institute, Bristol, BS2 8ED, UK,
| | | | - Richard Edmondson
- 12Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St
- 13Mary's Hospital, Manchester, UK,
| | - Geoff D. Hall
- 14Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's
| | - Andrew Clamp
- 15Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre,
| | | | - Marcia Hall
- 17St James's Institute of Oncology, Leeds, LS9 7TF UK,
| | | | - Hani Gabra
- 18The Christie Hospital, Manchester, M20 4BX, UK,
- 19Nicola Murray Centre for Ovarian Cancer Research, MRC IGMM, University of Edinburgh, Edinburgh, EH4 2XR, UK,
| | - James Paul
- 4Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, G12 0YN, UK,
| | - Anna Supernat
- 1Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK,
| | - David Millan
- 20Mount Vernon Cancer Centre, Northwood, HA6 2RN, UK,
| | - Aoisha Hoyle
- 20Mount Vernon Cancer Centre, Northwood, HA6 2RN, UK,
| | - Gareth Bryson
- 20Mount Vernon Cancer Centre, Northwood, HA6 2RN, UK,
| | - Craig Nourse
- 2Institute of Cancer Sciences, University of Glasgow, G61 1QH, UK,
| | - Laura Mincarelli
- 2Institute of Cancer Sciences, University of Glasgow, G61 1QH, UK,
| | | | - Bauke Ylstra
- 3VU University Medical Center, Amsterdam 1007 MB, The Netherlands,
| | - Mercedes Jimenez-Linan
- 21Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer,
| | - Luiza Moore
- 21Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer,
| | - Oliver Hofmann
- 2Institute of Cancer Sciences, University of Glasgow, G61 1QH, UK,
- 22Imperial College, London, W12 0NN, UK,
| | | | - Iain A. McNeish
- 2Institute of Cancer Sciences, University of Glasgow, G61 1QH, UK,
- 5Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, UK,
- 18The Christie Hospital, Manchester, M20 4BX, UK,
| | - James D. Brenton
- 1Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK,
- 21Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer,
- 23Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, UK,Department of Pathology, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK,Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK,Centre for Cancer Research, University of Melbourne, VIC 3010 Australia,Department of Oncology, University of Cambridge, CB2 0XZ, UK
| |
Collapse
|
8
|
Banerjee S, Lewsley LA, Clamp A, krell J, Herbertson R, Glasspool R, Orbegoso C, Green C, Kristeleit R, Gourley C, Cambell C, Banerji U, Shepherd C, Brugger W, Chudleigh L, Hanif A, McNeish I, Paul J. OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer: Vistusertib. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD. Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet 2018; 50:1262-1270. [PMID: 30104763 PMCID: PMC6130818 DOI: 10.1038/s41588-018-0179-8] [Citation(s) in RCA: 239] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Accepted: 06/19/2018] [Indexed: 01/22/2023]
Abstract
The genomic complexity of profound copy number aberrations has prevented effective molecular stratification of ovarian cancers. Here, to decode this complexity, we derived copy number signatures from shallow whole-genome sequencing of 117 high-grade serous ovarian cancer (HGSOC) cases, which were validated on 527 independent cases. We show that HGSOC comprises a continuum of genomes shaped by multiple mutational processes that result in known patterns of genomic aberration. Copy number signature exposures at diagnosis predict both overall survival and the probability of platinum-resistant relapse. Measurement of signature exposures provides a rational framework to choose combination treatments that target multiple mutational processes.
Collapse
Affiliation(s)
| | | | | | - Darren Ennis
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | | | | | - Daoud Sie
- VU University Medical Center, Amsterdam, the Netherlands
| | - Liz-Anne Lewsley
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Aishah Hanif
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Cheryl Wilson
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Suzanne Dowson
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | | | - Michelle Lockley
- Barts Cancer Institute, Queen Mary University of London, London, UK
- University College London Hospital, London, UK
| | | | | | | | | | - Richard Edmondson
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK
- Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | | | | | - Charlie Gourley
- Nicola Murray Centre for Ovarian Cancer Research, MRC IGMM, University of Edinburgh, Edinburgh, UK
| | | | - Christina Fotopoulou
- Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK
| | - Hani Gabra
- Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK
- Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, UK
| | - James Paul
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Anna Supernat
- Cancer Research UK Cambridge Institute, Cambridge, UK
| | - David Millan
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
| | - Aoisha Hoyle
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
| | - Gareth Bryson
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
| | - Craig Nourse
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Laura Mincarelli
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | | | - Bauke Ylstra
- VU University Medical Center, Amsterdam, the Netherlands
| | | | | | - Oliver Hofmann
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
- Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia
| | | | - Iain A McNeish
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
- Beatson West of Scotland Cancer Centre, Glasgow, UK.
- Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK.
| | - James D Brenton
- Cancer Research UK Cambridge Institute, Cambridge, UK.
- Addenbrooke's Hospital, Cambridge, UK.
- Department of Oncology, University of Cambridge, Cambridge, UK.
| |
Collapse
|
10
|
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD. Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet 2018. [PMID: 30104763 DOI: 10.1038/s41588-018-0179-8]+[] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The genomic complexity of profound copy number aberrations has prevented effective molecular stratification of ovarian cancers. Here, to decode this complexity, we derived copy number signatures from shallow whole-genome sequencing of 117 high-grade serous ovarian cancer (HGSOC) cases, which were validated on 527 independent cases. We show that HGSOC comprises a continuum of genomes shaped by multiple mutational processes that result in known patterns of genomic aberration. Copy number signature exposures at diagnosis predict both overall survival and the probability of platinum-resistant relapse. Measurement of signature exposures provides a rational framework to choose combination treatments that target multiple mutational processes.
Collapse
Affiliation(s)
| | | | | | - Darren Ennis
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | | | | | - Daoud Sie
- VU University Medical Center, Amsterdam, the Netherlands
| | - Liz-Anne Lewsley
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Aishah Hanif
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Cheryl Wilson
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Suzanne Dowson
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | | | - Michelle Lockley
- Barts Cancer Institute, Queen Mary University of London, London, UK.,University College London Hospital, London, UK
| | | | | | | | | | - Richard Edmondson
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK.,Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | | | | | - Charlie Gourley
- Nicola Murray Centre for Ovarian Cancer Research, MRC IGMM, University of Edinburgh, Edinburgh, UK
| | | | - Christina Fotopoulou
- Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK
| | - Hani Gabra
- Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK.,Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, UK
| | - James Paul
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Anna Supernat
- Cancer Research UK Cambridge Institute, Cambridge, UK
| | - David Millan
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
| | - Aoisha Hoyle
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
| | - Gareth Bryson
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
| | - Craig Nourse
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Laura Mincarelli
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | | | - Bauke Ylstra
- VU University Medical Center, Amsterdam, the Netherlands
| | | | | | - Oliver Hofmann
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.,Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia
| | | | - Iain A McNeish
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. .,Beatson West of Scotland Cancer Centre, Glasgow, UK. .,Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK.
| | - James D Brenton
- Cancer Research UK Cambridge Institute, Cambridge, UK. .,Addenbrooke's Hospital, Cambridge, UK. .,Department of Oncology, University of Cambridge, Cambridge, UK.
| |
Collapse
|
11
|
Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, Cuccia L, Spasiano A, Filosa A, Caruso V, Hanif A, Meloni A. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective. Clin Drug Investig 2017; 37:453-464. [PMID: 28185140 DOI: 10.1007/s40261-017-0496-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
PURPOSE Deferiprone (DFP), deferasirox (DFX) and deferoxamine (DFO) are used in thalassaemia major (TM) patients to treat chronic iron overload. We evaluated the cost-effectiveness of DFP, compared with DFX and DFO monotherapy, from an Italian healthcare system perspective. METHODS A Markov model was used over a time horizon of 5 years. Italian-specific cost data were combined with Italian efficacy data. Costs and quality-adjusted life years (QALYs) were calculated for each treatment, with cost-effectiveness expressed as cost per QALY. RESULTS In all scenarios modelled, DFP was the dominant treatment strategy. Sensitivity analyses showed that DFP dominated the other treatments with a >99% likelihood of being cost-effective against DFX and DFO at a willingness to pay threshold of €20,000 per QALY. CONCLUSIONS DFP was the dominant and most cost-effective treatment for managing chronic iron overload in TM patients. Its use can result in substantial cost savings for the Italian healthcare system.
Collapse
Affiliation(s)
- Alessia Pepe
- Magnetic Resonance Imaging Unit, Fondazione G. Monasterio CNR-Regione Toscana, Area della Ricerca S. Cataldo, Via Moruzzi, 56124, Pisa, Italy.
| | - Giuseppe Rossi
- Epidemiology and Biostatistics Unit, Institute of Clinical Physiology, CNR, Pisa, Italy
| | | | - Maria Caterina Putti
- Dipartimento di Pediatria, Clinica di Emato-Oncologia Pediatrica, Università di Padova/Azienda Ospedaliera, Padua, Italy
| | - Ludovica Frizziero
- Dipartimento di Pediatria, Clinica di Emato-Oncologia Pediatrica, Università di Padova/Azienda Ospedaliera, Padua, Italy
| | | | - Liana Cuccia
- U.O.C. Ematologia con Talassemia, ARNAS Ospedale Civico, Palermo, Italy
| | - Anna Spasiano
- U.O.S.D. Centro per le Microcitemie, AORN Cardarelli, Naples, Italy
| | - Aldo Filosa
- U.O.S.D. Centro per le Microcitemie, AORN Cardarelli, Naples, Italy
| | | | - Aishah Hanif
- Decision Resources Group Abacus, Bicester, Oxfordshire, UK
| | - Antonella Meloni
- Magnetic Resonance Imaging Unit, Fondazione G. Monasterio CNR-Regione Toscana, Area della Ricerca S. Cataldo, Via Moruzzi, 56124, Pisa, Italy
| |
Collapse
|
12
|
Glasspool RM, Blagden SP, Lockley M, Paul J, Hopkins C, Thomson F, Brown J, Fernandes R, Douglas N, Pou C, Hanif A, Campbell C, Multani PS, Tucker T, McNeish IA, Evans TJ. A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.2594] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2594 Background: Aberrant Hedgehog (Hh) signaling is implicated in carcinogenesis and is associated with poor prognosis in multiple tumours types. Hh inhibitors increase sensitivity to paclitaxel in taxane-resistant cell lines. Taladegib is an orally bioavailable, potent inhibitor of Smoothened, a key Hh pathway component, with activity in basal cell carcinoma. The single agent recommended dose is 400mg od. We present the dose escalation phase of a phase I study of weekly paclitaxel with oral taladegib. Methods: Primary objective: determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of taladegib on a continuous oral daily dosing regimen in combination with paclitaxel (80mg/m2, iv, day 1, 8 and 15 q 28) in patients with advanced solid cancers. Secondary objectives: assess the safety and tolerability, determine the recommended phase II dose (RP2D), and evaluate the pharmacokinetics of taladegib and paclitaxel. Exploratory objective: assess preliminary efficacy. A standard 3 + 3 dose escalation design was used. All patients received up to 6 cycles of paclitaxel. In addition, successive cohorts received continuous oral taladegib continued until progression or unacceptable toxicity as follows: dose level 1: 100mg od; 2: 200mg od; 3: 400mg od. Results: No DLTs were seen at dose level 1 or in the first 3 patients at dose level 2. 3 DLTs of grade 2 neuropathy were seen at dose level 3 (400mg taladegib); therefore, dose level 2 was expanded to 6 patients. No DLT was seen in the fourth patient and 2 additional patients have started treatment. After the DLT period 2 patients developed G2 and 4 developed G1 neuropathy. Other non DLT, drug-related G3 toxicities: uncomplicated neutropenia x2, muscle cramp x1 and fatigue x1. To date, 3 patients have had partial responses. Conclusions: The combination of daily oral taladegib and weekly paclitaxel is feasible. DLT of G2 neuropathy was seen at 400mg. Promising activity has been seen in solid tumours. A dose expansion cohort is due to commence in high grade ovarian carcinoma. ISRCTN No:ISRCTN15903698 Eudract Ref:2014-004695-37 Funded by Cancer Research UK C8361/A18775 and Ignyta. Sponsored by NHS Greater Glasgow and Clyde. Clinical trial information: ISRCTN15903698.
Collapse
Affiliation(s)
| | | | | | - James Paul
- University of Glasgow, Cancer Research UK Clinical Trials Unit, Glasgow, United Kingdom
| | | | | | - Jennifer Brown
- Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | | | - Nivea Douglas
- University College London Hospitals, London, United Kingdom
| | | | | | | | | | | | - Iain A. McNeish
- Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland
| | - T.R. Jeffry Evans
- University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| |
Collapse
|
13
|
Banerjee SN, Lewsley LA, Clamp AR, Gabra H, Herbertson R, Green C, Orbegoso C, Wilson C, Banerji U, Hanif A, McNeish IA, Paul J. OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer—Vistusertib (AZD2014). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.tps5609] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS5609 Background: There is an urgent need to improve outcomes for patients with platinum-resistant and refractory ovarian cancer (PROC). OCTOPUS is an umbrella phase II framework for testing whether the addition of novel targeted agents to weekly paclitaxel (wPxl) improves efficacy in PROC. The first agent to be evaluated is the dual mTORC1/mTORC2 inhibitor, vistusertib (AZD2014), as preclinical studies support targeting the PI3kinase/Akt/mTOR pathway in PROC and the combination of vistusertib and wPxl has shown promising preliminary activity in high grade serous ovarian cancer (HGS) patients in a phase I trial (Banerji et al poster discussion ESMO 2016). This is the first randomised trial of wPxl and a dual mTORC1/2 inhibitor in ovarian cancer. Methods: OCTOPUS is an investigator-initiated, randomised, double-blind, placebo-controlled, multicentre, phase II trial. 140 patients with PROC (histologically confirmed HGS) are randomised 1:1 to receive wPxl (80mg/m2 D1, D8, D15 of 28 day cycle) plus oral vistusertib (50mg BD) or placebo (D1-3, D8-10, D15-17). The primary endpoint is progression-free survival (PFS) based on combined RECIST v1.1/GCIG CA125 criteria. The study is designed to detect a 50% improvement in median PFS from 3.7 months on placebo to 5.55 months on the experimental arm with 90% power, at the 20% 1-sided level of statistical significance (or equivalently with 80% power at the 10% level of statistical significance) using a 3-outcome design. Secondary endpoints include response (based on RECIST 1.1 and GCIG CA125 criteria), overall survival, toxicity and quality of life. Patients whom received prior wPxl for PROC are not eligible. A mandatory pre-treatment biopsy (if technically feasible), archival tissue, and serial blood samples will be collected for translational research studies. 49 patients have been recruited. The study is part of the NIHR CRN Cancer/Astrazeneca Alliance, sponsored by NHS Greater Glasgow and Clyde/University of Glasgow and endorsed by Cancer Research UK (CRUKE/14/052). Clinical trial information: ISRCTN16426935.
Collapse
Affiliation(s)
| | | | - Andrew R. Clamp
- The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom
| | - Hani Gabra
- Imperial College London, London, United Kingdom
| | | | - Clare Green
- University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
| | | | - Cheryl Wilson
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Udai Banerji
- The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
| | | | - Iain A. McNeish
- Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland
| | - James Paul
- University of Glasgow, Cancer Research UK Clinical Trials Unit, Glasgow, United Kingdom
| |
Collapse
|
14
|
Akram Z, Abduljabbar T, Hanif A, Khan A, Vohra F. Attitude and knowledge of family medicine practitioners towards the association between periodontal disease and obesity. Niger J Clin Pract 2017; 20:595-599. [PMID: 28513519 DOI: 10.4103/1119-3077.197017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES To assess the attitude and knowledge of family medicine practitioners (FMPs) towards the association between periodontal disease and obesity. MATERIALS AND METHODS A cross-sectional study was performed and a 13-item survey questionnaire was given to FMPs practicing in 12 different teaching hospitals in Karachi, Pakistan. The questions were aimed at exploring the knowledge of FMP's regarding the association of obesity and periodontal disease and their attitude towards the association of obesity and periodontal disease. Chi-square and Spearman co-efficient were conducted to compare subgroups and correlate factors with the knowledge score of FMPs. RESULTS A total of 314 questionnaires were completed (response rate = 92%). Median age of participants was 41 years and 57% were females. Almost 61% of FMPs answered all the knowledge questions correctly and 64% reported moderate understanding of the association between periodontal health and obesity. Nearly 73% FMPs inquired from obese patients regarding the periodontal disease and more than half (58%) refer patients to a dentist for evaluation. More than half of FMPs perform periodontal disease screening. Nearly all FMPs considered informing obese patients regarding periodontal disease as one of their roles. CONCLUSIONS FMP's play an important role in the early diagnosis, prevention and treatment of periodontal conditions in obese patients. More than two thirds of FMPs showed good knowledge of the association of obesity and periodontal disease. The attitudes of FMPs towards assessing and referring obese patients at a risk of having periodontal disease were reassuring.
Collapse
Affiliation(s)
- Z Akram
- Faculty of Dentistry, Department of Restorative Dentistry, University of Malaya, Kuala Lumpur, Malaysia; Faculty of Dentistry, Department of Periodontology, Ziauddin University, Karachi, Pakistan
| | - T Abduljabbar
- Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University, Riyadh, Saudi Arabia
| | - A Hanif
- Faculty of Dentistry, Department of Periodontology, Ziauddin University, Karachi, Pakistan
| | - A Khan
- Family Medicine Resident, Ziauddin University Hospital, Ziauddin University, Karachi, Pakistan
| | - F Vohra
- Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University, Riyadh, Saudi Arabia
| |
Collapse
|
15
|
Chaudhary LN, Jawa Z, Hanif A, Szabo A, Chitambar CR. Abstract P6-09-37: Ductal carcinoma in situ: Patient outcomes and association with hormone receptors. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Local recurrence is a major concern in patients (pts) diagnosed with ductal carcinoma in situ (DCIS). Therefore, the need to identify pts at risk for DCIS recurrence is a significant priority. In invasive breast cancers, ER+/PR- subtype is considered a more aggressive tumor phenotype with poorer prognosis as compared to ER+/PR+ tumors. It is unclear whether this molecular subtype holds the same significance in pts with DCIS.
Methods
We designed an analysis to determine if a significant difference exists in the recurrence rates in pts with ER+/PR- DCIS when compared to ER+/PR+ tumors. Six hundred and ninety three pts diagnosed and treated for DCIS at Froedtert & MCW Clinical Cancer Center from Feb 2002-March 2015 were included in our study. Recurrence was defined as either non-invasive or invasive ipsilateral, contralateral or distant disease. Probabilities of recurrences were calculated using Kaplan-Meier estimator. Cox proportional hazards model was used to evaluate the effect of prognostic factors on DCIS recurrence.
Results
Median follow up was 5.2 years. Five year recurrence free survival (RFS) was 91% (95% CI 88.2-93.3) while estimated 7 year RFS was 86% (95% CI 81.9-89.2). Patient characteristics are shown in table below. Seventy five pts were found to have a recurrence during their follow-up. Most of the grade 1 tumors were ER+/PR+ whereas almost all of the ER-/PR- subtype were high grade tumors. ER+/PR- tumors were mainly intermediate and high grade (p <0.0001). Pts with ER-/PR- tumors had a significantly higher risk of recurrence (HR 3.7, 95% CI 1.9-7.2, p=0.0001) and those with ER+/PR- tumor subtype did not have a statistically significant difference in risk of recurrence when compared to ER+/PR+ tumors (HR 1.75, 95% CI 0.92-3.32, p=0.085). Pts who did not receive endocrine therapy for their ER+ DCIS had a significantly higher risk of recurrence as compared to those who received endocrine therapy (HR 2.2, 95% CI 1.23-3.92, p=0.0073). When compared to pts undergoing lumpectomy and radiation, pts undergoing lumpectomy alone had a significantly higher risk of recurrence (HR 2.5, 95% CI 1.32-4.93, p=0.005) whereas those who underwent mastectomy had a significantly lower risk of recurrence (HR 0.34, 95% CI 0.15-0.8, p=0.014).
Patient characteristicsCharacteristicsN (%)Total no. of patients693Median age53 (21-91)Median BMI27 (17-65)Post-menopausal480 (69)OCP use301 (43)HRT use201 (29)Tumor characteristics Median size0.8cm (0.2-6.5)Histology Solid349 (52)Cribriform290 (43)Papillary35 (5)Comedo necrosis423 (61)ER/PR status ER+/PR+482 (71.2)ER+/PR-77 (11.4)ER-/PR-118 (17.4)Tumor grade Low125 (18)Intermediate305 (45)High250 (37)Treatment Lumpectomy517 (75)Mastectomy169 (25)Radiation450 (66)Endocrine therapy286 (42)Patients with recurrence75 (11)Type of recurrence In-situ44 (6)Invasive31 (5)BMI=body mass index, OCP=oral contraceptive pills, HRT=hormone replacement therapy
Conclusion
ER+/PR- subtype was not a significant predictor of recurrence in DCIS patients. This finding is in contrast to the risk of recurrence and tumor aggressiveness seen in invasive breast cancers. Mastectomy and post lumpectomy radiation were associated with improved outcomes as was adjuvant endocrine therapy.
Citation Format: Chaudhary LN, Jawa Z, Hanif A, Szabo A, Chitambar CR. Ductal carcinoma in situ: Patient outcomes and association with hormone receptors [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-37.
Collapse
Affiliation(s)
| | - Z Jawa
- Medical College of Wisconsin, Milwaukee, WI
| | - A Hanif
- Medical College of Wisconsin, Milwaukee, WI
| | - A Szabo
- Medical College of Wisconsin, Milwaukee, WI
| | | |
Collapse
|
16
|
Dasgupta S, Divekar S, Arya A, Gupta P, Chauhan R, Bhadauria S, Hanif A, Garg MO, Nanoti A. A vapor phase adsorptive desulfurization process for producing ultra low sulphur diesel using NiY zeolite as a regenerable adsorbent. RSC Adv 2015. [DOI: 10.1039/c5ra05664k] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A NiY zeolite based vapor phase adsorptive desulfurization process has been described which can bring down sulphur concentration of a commercial BS IV grade (Euro IV equivalent) diesel from 50 ppm to a <5 ppm level.
Collapse
Affiliation(s)
- S. Dasgupta
- CSIR-Indian Institute of Petroleum
- AMS Laboratory
- Dehradun 248005
- India
| | - S. Divekar
- CSIR-Indian Institute of Petroleum
- AMS Laboratory
- Dehradun 248005
- India
| | - A. Arya
- CSIR-Indian Institute of Petroleum
- AMS Laboratory
- Dehradun 248005
- India
| | - P. Gupta
- CSIR-Indian Institute of Petroleum
- AMS Laboratory
- Dehradun 248005
- India
| | - R. Chauhan
- CSIR-Indian Institute of Petroleum
- AMS Laboratory
- Dehradun 248005
- India
| | - S. Bhadauria
- CSIR-Indian Institute of Petroleum
- AMS Laboratory
- Dehradun 248005
- India
| | - A. Hanif
- CSIR-Indian Institute of Petroleum
- AMS Laboratory
- Dehradun 248005
- India
| | - M. O. Garg
- CSIR-Indian Institute of Petroleum
- AMS Laboratory
- Dehradun 248005
- India
| | - A. Nanoti
- CSIR-Indian Institute of Petroleum
- AMS Laboratory
- Dehradun 248005
- India
| |
Collapse
|
17
|
Hussain MM, Talukder HK, Moazzem N, Rashid A, Hanif A, Nargis T. Evaluation of existing curriculum (2002) of undergraduate medical education in Bangladesh. Mymensingh Med J 2011; 20:226-232. [PMID: 21522092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
This study was conducted for evaluation of existing MBBS curriculum (2002) of undergraduate medical education in Bangladesh. The specific objectives of this study were: i) to assess the subject wise course content coverage in the new MBBS curriculum, ii) to assess different examination system for evaluation of MBBS students, iii) to evaluate the effectiveness of teaching and learning activities under the curriculum, iv) to explore students opinions regarding improvement of new curriculum. This was a descriptive cross-sectional study. The study was conducted among the students of Dhaka medical colleges of Bangladesh in 2008. Data was collected by self administered structured questioner adopting convenient sampling method. About ninety percent students opined that the coverage of course content of subjects in the curriculum in Phase I was enough. In case of the subjects in phase II except community medicine more than four fifth of the students expressed their opinion about coverage of course content in the curriculum as enough. In case of phase III it was mentioned by most of the students that coverage of course content was enough. Study revealed that teaching methods were perceived suitable by about three fourth of the respondents, to achieve learning objectives. Most of the students expressed their positive views regarding practice of block posting teaching. More than three fourth of the students perceived that formative assessment was encouraging for students to become time bound learner and Structured Oral Examination (SOE) was fair on an average. Only 31(8.6%) of the respondents had opinion that Objective Structured Practical Examination (OSPE)/Objective Structured Clinical Examination (OSCE) was not well organized. About half of the students opined that 20% marks in written test should be allocated for Multiple Choice Question (MCQ). Students' suggestions regarding teaching were: there should be smaller group sessions; more interactive sessions; more clinical and practical sessions; more problem oriented sessions; more sessions with senior and experienced teachers; teachers should follow the curriculum properly; and should be well prepared for class. Regarding assessment suggestions were: written script of the formative examination should be returned to students with feedback; teachers should not be biased. Study recommended that training of the teachers on teaching methodology and assessment system is needed; teachers should provide feedback to the students according to the performance of the formative assessment at the individual level; to maintain the standards of assessment proper planning, designing, conduction and evaluation of assessment should be taken into consideration; subject wise review and updating is essential to make the curriculum more need based, user friendly and applicable considering context of Bangladesh.
Collapse
|
18
|
Hanif A, Hasina K, Hassan K, Islam MS, Karim MS, Alam MU. Plasma Renin in ipsilateral renal vein in patients with chronic unilateral pelvic ureteric junction obstruction. Mymensingh Med J 2010; 19:543-548. [PMID: 20956897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Acute experimental hydronephrosis induces increased output of renin from ipsilateral kidney. In most clinical presentation of unilateral hydronephrosis the patients are however, normotensive with normal circulating plasma renin activity. In consideration of this argument we undertook this prospective study of ipsilateral renal vein renin activity in children with congenital Pelvic Ureteric Junction Obstruction (PUJO) and compared with other wise normal children. In this prospective cross-sectional study, started from July 99 to June 2001, twenty patients, age upto 12 years, with unilateral hydronephrosis and in control group ten patients without hydronephrosis were taken. 2ml blood was taken from the renal vein in study group and from infrarenal portion of inferior vena cava during exploratory laparotomy from the control group. All the patients had advanced grade of hydronephrosis and two patients (13%) had mild hypertension. In this study the mean plasma renin activity (PRA) was 45.58 ng/ml/hr (range: 11.69-67.56 ng/ml/hr) in study group. The mean PRA in control group was 5.9ng/ml/hr. The result of study group was significantly higher than normal (P value 0.0003). In Bangladesh we are doing more conservative kidney preserving surgery for PUJO, but need long term follow up of the patients undergoing surgery for PUJO in childhood for potential of developing renin-angiotensin induced hypertension in later life.
Collapse
Affiliation(s)
- A Hanif
- Department of Pediatric Surgery, Dhaka Medical College & Hospital (DMCH), Dhaka, Bangladesh.
| | | | | | | | | | | |
Collapse
|
19
|
Khan M, Nazir S, Ijaz T, Imran M, Hanif A, Shahzad M. Risk Assessment of Tuberculosis Prevalence in Sahiwal District of Punjab, Pakistan. Int J Infect Dis 2008. [DOI: 10.1016/j.ijid.2008.05.911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
20
|
Hanif A, Bakopoulos V, Leonardos I, Dimitriadis GJ. The effect of sea bream (Sparus aurata) broodstock and larval vaccination on the susceptibility by Photobacterium damsela subsp. piscicida and on the humoral immune parameters. Fish Shellfish Immunol 2005; 19:345-361. [PMID: 15863015 DOI: 10.1016/j.fsi.2004.12.009] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2004] [Revised: 12/06/2004] [Accepted: 12/22/2004] [Indexed: 05/24/2023]
Abstract
Sea bream broodstock were immunised 1 or 2 months before spawning with a novel photobacteriosis vaccine. Sixty-seven-day-old larvae (mean weight 22.3 mg) originating from immunised and non-immunised parents were experimentally infected with the Photobacterium damsela subsp. piscicida (Phdp). Larvae from immunised fish showed delayed onset and lower mortality (66.67%) compared with larvae from control fish (80%). Eighty-nine-day-old larvae (mean weight 162.2 mg) from both groups were bath vaccinated with Phdp and Escherichia coli lipopolysaccharides (LPS) and larval samples were collected for measurement of humoral parameters. Larvae vaccinated with Phdp and LPS showed significantly higher anti-protease activity, lysozyme activity and total immunoglobulin compared to the controls. One-hundred-and-twenty-day-old larvae (mean weight 297.85 mg) from both parental groups were challenged with (LD70) virulent Phdp bacterial cells. Vaccinated larvae from both groups showed significantly less mortality compared to the respective controls. The RPS values of larvae from immunised parents vaccinated with Phdp and LPS was 95.83% and 72.22%, respectively. The RPS values of larvae from non-immunised parents vaccinated with Phdp and LPS was 62.5% and 70.83%, respectively. Results are discussed with respect to the beneficial effect of broodstock immunisation prior to spawning and the immunisation of larvae on their survival against photobacteriosis.
Collapse
Affiliation(s)
- A Hanif
- Division of Genetics, Department of Biology, University of Patras, Patras 26500, Greece
| | | | | | | |
Collapse
|
21
|
Hanif A, Bakopoulos V, Dimitriadis GJ. Maternal transfer of humoral specific and non-specific immune parameters to sea bream (Sparus aurata) larvae. Fish Shellfish Immunol 2004; 17:411-435. [PMID: 15313509 DOI: 10.1016/j.fsi.2004.04.013] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/14/2004] [Revised: 04/13/2004] [Accepted: 04/20/2004] [Indexed: 05/24/2023]
Abstract
Immunisation of sea bream (Sparus aurata L.) broodstock with a novel vaccine mixture of Photobacterium damsela subsp. piscicida SK7 (Phdp) was performed during the period of egg development and the changes in specific and non-specific humoral immune parameters were measured. Total immunoglobulin level, specific antibody titre, anti-protease activity and lysozyme activity were significantly higher in immunised parents compared to the control. After spawning significantly higher anti-protease activity, lysozyme activity and total immunoglobulin level were detected in the eggs from immunised parents. Specific antibody titres against Phdp were only detected in the eggs from the immunised parents. The larvae from immunised parents also expressed significantly higher levels of specific and non-specific humoral immune parameters compared to the controls. A small amount of total immunoglobulin was detected in larvae decreasing gradually until day 8 post-hatching and then an increase was measured in larvae from immunised parents, whereas no immunoglobulin was detected at days 4, 6 and 8 in larvae from non-immunised parents. The specific antibody titre against Phdp was detected only in larvae from immunised broodstock until day 14 post-hatching. The higher humoral immune parameters in eggs and larvae from immunised parents in comparison to eggs and larvae from non-immunised parents, suggest transfer of maternal specific and non-specific immune factors.
Collapse
Affiliation(s)
- A Hanif
- Division of Genetics, Department of Biology, University of Patras, Patras 26500, Greece
| | | | | |
Collapse
|
22
|
Bakopoulos V, Hanif A, Poulos K, Galeotti M, Adams A, Dimitriadis GJ. The effect of in vivo growth on the cellular and extracellular components of the marine bacterial pathogen Photobacterium damsela subsp. piscicida. J Fish Dis 2004; 27:1-13. [PMID: 14986934 DOI: 10.1046/j.1365-2761.2003.00513.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Photobacterium damsela subsp. piscicida, the causative agent of fish pasteurellosis, was grown in vivo. Bacterial cells and extracellular products (ECPs) were analysed via electrophoresis and immunoblot analysis, using specific sea bass antisera. Growth in vivo induced the synthesis of unique bacterial cell proteins at > 206, 206, 21.3, 18, 7.6 and < 7.6 kDa. Sea bass serum raised against live bacterial cells of the pathogen and especially a sea bass serum raised against formalin-inactivated bacterial cells grown in a specific novel medium recognized the novel antigens at > 206 (associated with iron sequestration), 21.3, 7.6 and < 7.6 kDa, suggesting that the latter medium conserves the synthesis of natural bacterial cell proteins in vitro. In vivo growth of the pathogen induced the synthesis of more toxic ECPs in comparison with in vitro growth and an inverse correlation between total protein concentration in the ECPs and toxicity per unit of protein was observed. Substrate-polyacrylamide electrophoresis revealed the presence of in vivo synthesized ECPs of the pathogen (proteases) at 175, 132, < 79 and 48.3 kDa. Histological examination of tissues isolated from fish injected with these ECPs revealed inflammatory and necrotic lesions in the spleen, liver, head kidney, intestine and heart as soon as 48 h post-introduction of the ECPs.
Collapse
Affiliation(s)
- V Bakopoulos
- Division of Genetics, Department of Biology, University of Patras, Greece
| | | | | | | | | | | |
Collapse
|
23
|
Aziz MA, Hossain AZ, Banu T, Karim MS, Islam N, Sultana H, Alam MI, Hanif A, Khan AR. In hydronephrosis less than 10 % kidney function is not an indication for nephrectomy in children. Eur J Pediatr Surg 2002; 12:304-7. [PMID: 12469255 DOI: 10.1055/s-2002-35956] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
PURPOSE To reduce the incidence of nephrectomy or hydronephrosis in children. MATERIALS AND METHODS From September 1998 to October 2000, we treated 58 patients with hydronephrosis; their ages ranged from 35 days to 11 years (mean age 4 years 7 months). All patients were subjected to a DTPA renogram with split function. In 12 patients (study group), kidney function was less than 10 % (range 0 - 10 %). Initially, nephrostomy was carried out in all 12 patients followed by Anderson-Hyne's pyeloplasty after 4 - 6 weeks. Postoperatively renal USG, urine r/m/e & c/s (routine and microscopic examination and culture and sensitivity test), blood urea, serum creatinine were assessed and DMSA scan and DTPA renogram with split functions were carried out in all patients. RESULTS In the study group, all 12 patients showed improvement of renal function (more than 10 %) after nephrostomy and in all of them pyeloplasty was subsequently carried out within 4 - 6 weeks. There were no significant pre-, peri- or postoperative complications. CONCLUSIONS Contrary to common practice we do not recommend nephrectomy for hydronephrotic kidneys which show < 10 % of renal function on renogram. The renal functional status improves significantly after a preliminary nephrostomy, thus avoiding the need for a straightforward nephrectomy in children along with all the possible long-term effects of a single kidney.
Collapse
Affiliation(s)
- M A Aziz
- Department of Surgery, BICH & Dhaka Shishu (Children's) Hospital, Dhaka, Bangladesh.
| | | | | | | | | | | | | | | | | |
Collapse
|